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Summary Following a single injection of 7.5 x 107 U kg-' of human recombinant tumour necrosis factor-
alpha (TNF-a) to female NMRI mice, marked hypoglycaemia was observed within a 2 h period, accompanied
by a severe depletion of liver glycogen and a drop in rectal body temperature when compared with pair-fed
controls. There was no alteration in plasma alanine, lactate or pyruvate values, but an elevation of
acetoacetate and 3-hydroxybutyrate when compared with pair-fed controls. Production of 4CO2 from U-14C-
glucose was reduced in TNF-a treated animals, while production of 4CO2 from U-'4C-palmitate was not
significantly different from controls, suggesting that the glucose was not being used to provide an increased
metabolic rate. Glucose utilisation by different tissues was investigated by the 2-deoxyglucose tracer method.
This showed that 2 h following TNF-a infusion glucose utilisation was increased in colon, liver, kidney and
spleen by 500, 350, 36 and 25% respectively. However, when calculated on a whole-animal basis the major
contributor to the increased glucose consumption was the liver. Plasma levels of both FFA and triglycerides
were also elevated in TNF-a treated animals, suggesting that increased consumption of glucose by the liver
may be utilised for lipogenesis. The rate of conversion of glucose into lipids in the liver was more than
doubled 2 h after TNF-a administration with a concomitant rise in plasma and adipose tissue. These results
suggest that administration of TNF-a produces a severe hypoglycaemia in order to serve an increased
lipogenesis in liver and adipose tissue, which appears to be independent of the anorectic effect.
Tumour necrosis factor-alpha (TNF-a) is a macrophage pro-
duct secreted in response to endotoxin stimulation (Beutler et
al., 1985a). Many of the lethal effects of endotoxin can be
reproduced by TNF-a administration (Tracey et al., 1986)
and complete protection against septic shock during lethal
bacteraemia can be obtained with anti-TNF-a monoclonal
antibodies (Tracey et al., 1987). In addition endotoxin
activated macrophages produce a mediator (cachectin) that
evokes a state of cachexia in recipient animals (Cerami et al.,
1985). The N-terminal sequence of mouse cachectin has been
shown to be homologous to TNF-a (Beutler et al., 1985b)
and mice bearing CHO cells transfected with the human
TNF/cachectin gene have been shown to develop severe
cachexia and weight loss (Oliff et al., 1987). Weight loss
associated with TNF-x administration to rodents is accom-
panied by a reduction in both food (Oliff et al., 1987; Tracey
et al., 1988; Mahony et al., 1988) and water (Mahony et al.,
1988) intake and can be abolished by the administration of
anti-cachectin antibodies (Tracey et al., 1987).
Although it seems clear that TNF-x can produce a state of
weight loss in experimental animals this differs from the
cachexia of cancer where weight loss often occurs without a
drop in food or water intake (Mahony et al., 1988). Also
TNF-o has not been detected in the serum of patients with
clinical cancer cachexia (Socher et al., 1988) and there is no
evidence of accelerated cachexia in cancer patients receiving
TNF-o as a 5-day continuous intravenous infusion (Sherman
et al., 1988). However, TNF-a administration causes marked
biochemical changes, in particular a severe hypoglycaemia
and a hypertriglyceridaemia 24 h after administration, al-
though the time course for these changes has not been deter-
mined (Mahony et al., 1988). The mechanism of weight loss
induced by TNF-m and its relationship to hypophagia and
hypoglycaemia remain unclear. The present report was
designed to further investigate the mechanism of the hypo-
glycaemic effect induced by TNF-<x and its relationship with
hypertriglyceridaemia and weight loss.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) were bred in our
own colony and were fed ad libitum a rat and mouse
breeding diet (Pilsbury's, Birmingham, UK).
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TNF
Human recombinant tumour necrosis factor-a (TNF-a)
(6 x I07 U mg-') was kindly donated by Boehringer Ingel-
heim Ltd (Bracknell, Berks, UK) and was stored at 4°C. The
endotoxin content was less than 0.125 EU ml-'. Fresh solu-
tions of TNF-a were made up in 0.9% NaCl and 200 li was
injected into the tail veins of female NMRI mice (18-20 g) to
give a dose of 7.5 x 107 U kg-'. Control animals were pair-
fed and injected with 200ttl of 0.9% NaCI. Female mice were
chosen for this study since they are less aggressive than
males, which can lead to food deprivation in individual
animals. Blood was removed by cardiac puncture from
animals under anaesthesia at specified time intervals after the
injection and blood metabolite levels determined.
Metabolite determinations
Blood glucose was determined on whole blood with the use
of the o-toluidine reagent kit (Sigma Chemical Co., Dorset,
UK). Liver glycogen (Keppler & Decker, 1974), blood aceto-
acetate (Mellanby & Williamson, 1974), 3-hydroxybutyrate
(Williamson & Mellanby, 1974), L-alanine (Williamson,
1974), pyruvate (Czok & Lamprecht, 1974) and lactate (Gut-
man & Wahlefield, 1974) levels were determined by published
procedures. Plasma levels of free fatty acids (FFA) were
measured with a Wako NEFA C kit (Alpha Laboratories,
Hampshire, UK), and plasma triglycerides were determined
with a triglyceride diagnostic kit (Sigma Diagnostic, Dorset,
UK).
Rectal body temperature was measured at specified time
intervals using a thermocouple.
Effect of TNF-c on respiration and lipogenesisfrom glucose
Female NMRI mice (18-20g) were injected i.v. with 7.5 x
I07 U kg-' of TNF-a and control animals of the same weight
were pair-fed and injected i.v. with 0.9% NaCI. Animals were
then immediately injected i.p. with 50gpCi kg-' of either
D-U-'4C-glucose (sp. act. 270 mCi mmol-') or U-'4C-palmitic
acid (sp. act. 850 mCi mmol-'), (Amersham International,
Amersham, UK). Animals were placed in airtight metabolic
cages into which air was pumped through calcium carbonate
(solid) to absorb any CO2. Metabolically produced '4C02 was
trapped in a mixture of ethanolamine:ethoxyethanol (1:4)
and aliquots were taken at specified time intervals and the
radioactivity was determined directly in Optiphase scintilla-
tion fluid (FSA Laboratory Supplies, Loughborough, UK).
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To determine the effect of TNF-a on lipogenesis from
glucose animals were administered 7.5 x I07 U kg-' of TNF-
a as above and either immediately or I h later U'4C-glucose
(2501 Cikg-1) was administered as an i.p. injection. Blood
was removed by cardiac puncture from animals under anaes-
thesia 2h after injection of the '4C tracer and the livers,
spleens, epididymal fat pads and colon were removed. Lipids
were extracted by the method of Stansbie et al. (1976) and
the radioactivity was determined in Optiphase scintillation
fluid.
Glucose utilisation
The extent of glucose utilisation by different tissues was
investigated using the 2-deoxyglucose tracer technique (Mes-
zaros et al., 1987a). Briefly, animals were starved over-
night and throughout the experiment, but given water ad
libitum. The following day the mice were injected i.v. with
7.5 x 107 U kg-' TNF-a and 1 h later they were injected i.v.
with 50ts Ci kg-' of 2-deoxy-D-2,6-3H-glucose (sp. act.
42 mCi mmol-') (Amersham International, Amersham, UK).
In order to determine the retention of 2-deoxyglucose 6-
phosphate by the different tissues a third i.v. inject-
ion of 5, Ci kg-' of 2-1-'4C-deoxy-D-glucose (sp. act.
56 mCi mmol-') (Amersham International, Amersham, UK)
was administered 35 min after the injection of the tritiated
glucose. Blood was removed by cardiac puncture from
animals under anaesthesia at specified time intervals and
the decay of radioactivity in the blood was monitored for
60 min. Blood glucose concentration was determined as des-
cribed above. The accumulation of phosphorylated metabol-
ites of 2-deoxyglucose was measured in selected tissues at the
60 min time point (Meszaros et al., 1987a,b). Glucose utilisa-
tion was calculated according to the equation:
Cm* (T)
Rg =
LC x kIc .dt
where Rg is tissue glucose metabolic rate (nmol g-' min-');
Cm* (T) is the concentration of phosphorylated metabolites
of 2-deoxyglucose in the tissue (d.p.m. g-') at t = 60 min; Cp
is the blood glucose (nmol ml-'); Cp* is the concentration of
radioactive 2-deoxyglucose in the blood (d.p.m. ml-') and
LC (lumped constant) is a dimensionless correction factor for
discrimination against 2-deoxyglucose in glucose metabolic
pathways and was determined by a modification of the
method of Ferre et al. (1985). Briefly mice were killed by
cervical dislocation and the livers removed. The livers were
sliced and incubated in flasks containing 2 ml of Krebs
Ringer buffer, pH 7.4, containing 1% BSA, 5 mM glucose,
1 gs Ci D-U-'4C-glucose (sp. act. 270 mCi mmol' -) and 2ji Ci
of 2-deoxy-D-2,6-3H-glucose (sp. act. 42Cimmol-') (DG).
The medium was gassed with 02:CO2 (95:5) for 2 min, and
the flasks were fitted with a centre well and sealed with a
rubber seal. After incubation for 1 h at 37°C the tissues were
removed and analysed for 2-deoxyglucose-6-phosphate
(2DGP) content (Mesaros et al., 1987a,b). Lipids were ex-
tracted and analysed for '4C content as described above.
Labelled alanine and lactate were determined as described by
Ferre et al. (1978). Hyamine (0.5 ml) was injected into the
centre well of the incubation flasks and '4CO2 was liberated
from the medium by the addition of 0.5 ml of 40% (w/v)
perchloric acid.
LC = tissue 2 DGP/2DG in medium
glucose utilisation/glucose in medium
Results
We have previously shown that acute administration of
TNF-a caused a dose related weight loss over a 24 h
period (Mahony et al., 1988) and in order to investigate
the biochemical effects of TNF-x a single injection of
7.5 x 107 U kg-' was employed for further studies, since this
produced a weight loss of about 2 g without toxicity. The
effects on blood glucose levels are shown in Figure la. When
compared with saline-injected pair-fed controls TNF-a
caused an initial hyperglycaemia, within 0.5 h after injection,
and this was followed by a marked hypoglycaemia, which
was evident without 2 h and was maintained for a 24 h
period of study. The hypoglycaemia was accompanied by a
marked reduction in liver glycogen (about 80%) within 2 h
after injection (Figure lb), which was maintained for 4 h, but
thereafter there was a progressive increase in glycogen levels
such that by 8 h the level was not significantly different from
pair-fed controls. Administration of TNF-a also caused a
marked hypothermia as measured by rectal body temperature
(Figure lc), which was significantly different from pair-fed
controls at 0.5 h, and persisted up to 4 h. This suggests that
although there was a considerable drain on blood glucose, it
was not being utilised to provide energy for heat generation,
or that there was a defect with the thermoregulatory system.
An increased metabolic activity appears not to be respon-
sible for the decrease in blood glucose level since the rate of
production of '4CO2 from U-'4C-glucose in TNF-ax injected
animals was significantly lower than from saline-injected,
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Figure I Effect of a single injection ofTNF-a (7.5 x 107 U kg-')
on (a) blood glucose, (b) liver glycogen and (c) rectal body
temperature of female NMRI mice. Each point represents the
mean ± s.e.m. of 5-10 animals. *P< 0.001 from control, pair-
fed animals by Student's t test. Closed symbols TNF-a treated
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pair-fed controls (Figure 2a). In contrast production of '4CO2
from U-'4C-palmitic acid in TNF-u injected animals did not
differ from controls over a 24 h period (Figure 2b). The
decrease in glucose oxidation may be due to the reduced
uptake of glucose into muscle (Table I, Figure 4) in TNF-a
treated animals. The blood levels of pyruvate, lactate or
alanine did not change after TNF-x administration over an
8 h period when compared with saline-injected, pair-fed cont-
rols. However, by 24 h lactate levels were significantly higher
in TNF-a treated animals (2.6 ± 0.1 mM and 1.9 ± 0.4 mM;
P<0.05 by Student's t test).
Glucose utilisation by different tissues was investigated in
vivo by the 2-deoxyglucose tracer method (Meszaros et al.,
1987a,b; Ferre et al., 1985). Blood glucose levels in TNF-a
treated animals, that had previously been starved overnight,
were significantly lower than controls up to 45 min after
treatment (Figure 3a), although there was no difference in the
rate of disappearance of the label from 2-deoxy-D-2,6-3H-
glucose (3H-2DG) (Figure 3b) or of 2-1-_4C-deoxy-D-glucose
('4C-2DG) (Figure 3c) between the two groups. The tissue
glucose metabolic rate (Rg) of control and TNF-a injected
animals is given in Table I. The calculated lumped constant
for the liver was 0.45, which was close to the values
previously reported for other tissues (Meszares et al., 1987b;
Ferre et al., 1985) and so this value was utilised to calculate
the Rg values for all tissues. This shows that 2 h following
TNF-a injection the Rg values in colon, liver, kidney and
spleen were increased by 520, 340, 36 and 25% respectively
while the Rg values in thigh and gastrocnemius muscles were
decreased by 29 and 31% respectively. However, when cal-
culated on a whole organ basis it can be seen that the major
Table I Tissue glucose metabolic rate (Rg) 2 h after TNF-a
(7.5 x 107 U kg-') administrationa
Tissue Control TNF-c
Liver 80 4 248 15d
Brain 2039 105 1875 134
Spleen 1157 40 1446 77d
Kidney 413 61 561± 33c
Pancreas 661 ± 85 544± 33
Thigh 1012 106 721 97b
Gastrocnemius 1309 142 906 121C
Diaphragm 155 24 206± 29
Lung 1358 203 1200± 75
Stomach 249 45 176± 10
Colon 26 4 134 43d
aRg values are expressed as nmol glucoseg' min-' and are given as
mean ± s.e.m., n = 6; bP< 0.01 from controls by Student's t test;
cP< 0.005 from controls by Student's t test; dp< 0.001 from controls
by Student's t test.
contributor to an increased glucose utilisation, which may be
responsible for the decrease in blood glucose levels after
TNF-a administration, is the liver (Figure 4). The magnitude
of the contribution of glucose utilisation by the various
organs depends on both the increase in Rg value and the size
of a particular organ. Thus the contribution of the colon to
the total body increase in glucose consumption was modest,
although this organ showed the largest increase in Rg value
after TNF-a administration, because of the low contribution
to the total body mass.
To investigate whether TNF-a administration altered the
retention of 2DGP in the various organs we applied a
sequential double labelling technique (Meszaros et al., 1987a)
followed by an analysis of the two labels in 2DGP. Since
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Figure 2 Effect of TNF-a (7.5 x 107 U kg-') on the production
of "CO2 from D-U-'4C-glucose (a) or U-'4C-palmitate (b). Both
saline-injected pair-fed animals (El) and TNF-a (*) injected
animals were administered 50 glCi kg-' of the radioisotope
immediately after the first injection and the production of '4CO2
was determined as described in methods. Each point is the mean
+ s.e.m. for 5 animals. **P< 0.05 and *P< 0.001 from controls
by Student's t test.
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Figure 3 Plasma glucose concentration (a) and the disap-
pearance of 3H-2DG (b) or "'C-2DG (c) from the blood in
control (open symbols) and TNF-x (closed symbols) treated
animals. One hour after TNF-x administration (7.5 x 10' U kg-')
animals were injected with 50 IA Ci kg- of 3H-2DG and 35
minutes later with 5ptCi kg-' "C-2DG and serial blood samples
were removed at time intervals. Each point represents the mean
± s.e.m. of 5-10 animals.
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Figure 4 Glucose utilisation rates of different organs of the
mouse 2 h after infusion with saline (hatched boxes) or
7.5 x 107 U kg-' of TNF-a (closed boxes). The results are ex-
pressed as mean ± s.e.m. for 6 animals and were based on organ
weights and Rg values (Table I). A, liver; B, brain; C, spleen; D,
kidney; E, pancreas; F, thigh muscle; G, gastrocnemius muscle;
H, diaphragm, I, lung; J, stomach; K, colon.
there was a marked initial decay of the precursor in the
blood the bulk of the 2-3H-DGP was synthesised in the
tissues during the initial 35 min of the labelling period while
2-'4C-DGP was formed during the second 25 min period and
the 3H/'4C ratio of tissue 2DGP was measured at the end of
the experiment. Loss of 2DGP from the tissue would affect
the 3H component of the ratio more than the i4C component
and therefore the 3H/i4C ratio of 2DGP in the tissues was a
measure of the retention of 2DGP, i.e. a low ratio indicated a
high rate of loss. In these experiments the amount of 3H
radioactivity administered was 10 times higher than the i4C
and thus the 3H/'4C ratio would be expected to be near 10.
This was true for all control tissues except for brain and
kidney, which were much lower, and diaphragm, which was
much higher (Table II). The lower ratio for brain has
previously been reported (Meszaros et al., 1987a) and arises
from an increased rate of loss of 2DGP from this tissue. The
higher ratio for diaphragm indicates that the concentration
of 2-3H-DGP was still increasing over the second period.
However, after TNF-a administration the 3H/'4C ratios were
significantly lower in liver, brain, spleen and lungs, indicating
an increased rate of loss of 2DGP from these tissues (Table
II).
Since the increased glucose utilisation after TNF-x
administration is not associated with an increased respiratory
CO2 production (Figure 2a) or an increased blood lactate,
alanine or pyruvate level, it suggests increased anabolic reac-
tions. The plasma levels of both FFA (Figure 5a) and tri-
glycerides (Figure Sb) were increased markedly 2-8 h after a
single injection of TNF-a, while blood levels of both
acetoacetate (Figure 5c) and 3-hydroxybutyrate (Figure 5d)
were increased by 2 h and remained elevated for the 24 h
period study. This suggests that the increased glucose con-
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Figure 5 Effect of a single injection of TNF-a (7.5 x 10' U kg-')
on (a) plasma FFA, (b) plasma triglyceride, (c) blood
acetoacetate, (d) blood 3-hydroxybutyrate concentrations of
female NMRI mice. Each point represents the mean ± s.e.m. of
5-6 animals ***P< 0.05, **P< 0.01, *P< 0.001 from control
by Student's t test. Closed symbols TNF-a treated animals, open
symbols control.
sumption by the liver in TNF-a treated animals may be
utilised for the biosynthesis of lipids.
To investigate this possibility the conversion of U-i4C-
glucose into lipids in various organs was determined after
TNF-a administration. The results in Figure 6 show the
effect on liver, spleen, colon, adipose tissue and plasma. The
results are expressed as total organ synthesis since this might
Table II Labelling of 2DGP in tissues after sequential administration of2-'H-DG and 2-'4C-DGa
Control d.p.m. g-' tissue TNF-at d.p.m. g-' tissue
Tissue 3H-2DGP 14C-2DGP 3H/14C 3H-2DGP 14C-2DGP 3H/14C
Liver 2620± 290 180± 37 13.8 1.8 8183 49 1100 110 7.6 0.6c
Brain 67283 3455 9900 808 7.1 0.3 61880 4408 10520 863 5.9+ 0.6c
Spleen 38167 1319 3420 188 11.0 0.4 47700 2527 5933 196 8.1 0.4c
Kidney 13630 2000 2340 350 5.9 0.5 18520 1100 2750 100 6.8 0.6
Pancreas 21800±2800 1500±200 12.2 1.4 17950 1100 1870 110 9.7±0.5
Thigh 33400±3500 3100±400 10.3± 1.5 23800±3200 2720±400 9.2± 1.3
Gastrocnemius 43200 ± 4700 3880 ± 700 9.1 ± 0.8 29900 ± 4000 3550 ± 330 8.4 ± 1.1
Diaphragm 5110 800 340 50 18.4 4.1 6800 970 498 29 11.6 2.6
Lungs 44800 6700 4220 840 11.6 1.8 39600 2490 4750 310 8.4 0.2b
Stomach 8200 1500 700± 60 11.6 1.9 5810 330 740 120 8.9 1.6
Colon 858 130 128 28 6.6 2.1 4473 1425 804 107 7.5 2.2
aResults are mean ± s.e.m., n = 5- 10; bp< 0.05 from control by Student's t test; CP< 0.001 from control by Student's t
test.
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Figure 6 Effect of a single injection of TNF-a (7.5 x 107 U kg-')
on the conversion of U-'4C-glucose into lipids in adipose tissue,
spleen, blood, liver and colon 2 h (A and B) and 3 h (C and D) in
control (A and C) and TNF-a (B and D) treated animals.
Animals were administered U-'4C-glucose (250 I Ci kg-') and the
conversion to '4C lipids was determined as described in methods.
***P< 0.05, **P< 0.01, *P< 0.001 from control by Student's t
test. n = 6.
be expected to be of greater significance to total body lipid
homeostasis. Thus, 2 h after TNF-a administration conver-
sion of glucose into lipids in the liver is more than doubled
and this increase is reflected in an increased plasma level of
14C lipid and an increased synthesis in adipose tissue. At 3 h
after TNF-x administration the rate of conversion of 14C
glucose into lipid in the liver was still increased, but the level
in plasma was five times that of controls and the level in
adipose tissue about four times that of controls. Small in-
creases were also observed in the spleen, but not in the colon
at these times. These results suggests that TNF-a administra-
tion produces a severe hypoglycaemia in order to serve an
increased lipogenesis in liver and adipose tissue.
Discussion
Acute administration of TNF-a to female NMRI mice has
previously been shown to result in a dose-related weight loss,
which is directly proportional to a reduction in food and
water intake (Mahony et al., 1988; Mahony & Tisdale, 1988).
Intracerebroventicular microinfusion of TNF-a has also been
shown to suppress food intake in rats (Plata-Salaman, 1988)
possibly by inhibition by glucose-sensitive neurons in the
lateral hypothalamic area. Profound changes in blood
glucose levels occur, which are more severe than we have
observed in a tumour-bearing cachexia model (MAC16)
(Mahony et al., 1988). An initial hyperglycaemia following
TNF-a administration is followed by a dramatic reduction in
blood glucose levels below that observed in saline-injected,
pair-fed controls, suggesting that the decrease in blood
glucose levels is more related to the TNF-a than to the drop
in food intake. Similar results have been reported in experi-
mentally induced endotoxic shock (Filkins, 1984). A reduc-
tion in lipid absorption from the gastrointestinal tract has
been observed following TNF-a administration (Evans &
Williamson, 1988) and a reduced nutrient absorption may
lead to the sustained hypoglycaemia effect. Concomitant with
the reduction in blood glucose levels liver glycogen is reduced
by about 80% within 2 h after TNF-a administration and
remains below control values up to 8 h. The effect of TNF-x
on hepatic glycogen levels may be mediated via increased
circulatory levels of glucagon or catecholamines, which have
been shown to be increased, together with corticosterone
levels, after TNF-x administration (Warren et al., 1987a;
Bagby et al., 1988) correlating with an increased glucose rate
of appearance (Bagby et al., 1988). Previous studies have
shown no effect of TNF-x on glycogenolysis, gluconeogenesis
or ketogenesis in isolated rat hepatocytes in short term
incubations (Rofe et al., 1987) suggesting that the in vivo
effects may be mediated by secondary modifiers. Although
blood lactate levels have been reported to be elevated 3-5-
fold after TNF-x administration (Tracey et al., 1986) no
increase in blood lactate or pyruvate were observed over
short time intervals in this study and no change in blood
alanine levels. In humans TNF-a has been shown to cause an
increased release of the gluconeogenic amino acids alanine
and glutamine from forearm muscle and increase the uptake
into other tissues (Warren et al., 1987b), while in the rat
TNF-a has been shown to have no effect on skeletal protein
balance (Kettlehut & Goldberg, 1988). The plasma concen-
trations of both acetoacetate and 3-hydroxybutyrate were
elevated about 2-fold within 2 h after TNF-x administration.
Such elevations, which normally occur in prolonged starva-
tion, were not due to the reduction in food intake, since they
were not observed in pair-fed animals, and suggest elevated
production of acetyl CoA.
Despite the apparent drain on blood glucose levels conver-
sion of glucose into CO2 is reduced after TNF-a admin-
istration when compared with pair-fed animals, although
production of '4CO2 from U '4C-palmitate is not affected.
This again suggests that the reduction of blood glucose is not
due to oxidative metabolism and probably arises from an
increase in anabolic reactions.
In order to determine the organs responsible for increased
glucose consumption after TNF-x administration we applied
the 2-deoxyglucose tracer technique. For these experiments
animals were starved overnight, which itself reduced plasma
glucose to almost the TNF-a treated level (Figure 3a),
although it did not prevent TNF-a induced changes in
glucose consumption. Previous studies in rats (Meszaros et
al., 1987b) have shown an increased glucose utilisation by
spleen, liver, kidney, skin, diaphragm, lung and ileum after
TNF-a administration. When calculated on a whole animal
basis the major contributor to the increased glucose utilisa-
tion after TNF-a administration in this study was seen to be
the liver because of the greater size of this organ. The rate of
turnover of glucose using a double isotope labelling tech-
nique was also shown to be significantly elevated after TNF-
a administration.
Since the elevated glucose consumption is not due to con-
version into CO2 or lactate it suggests an enhanced lipo-
genesis. An enhanced hepatic fatty acid and sterol synthesis
has been observed after administration of TNF-x to the rat
(Feingold et al., 1987), and the increase in circulating lipid
levels after TNF-a administration can occur in the absence of
a TNF-induced inhibition of adipose tissue lipoprotein lipase
activity (Feingold et al., 1989; Chajek-Shaul et al., 1989).
Using U-'4C-glucose we have shown an elevated conversion
to lipids in the liver, adipose tissue and plasma of animals
after TNF-x administration. This suggests that the hyper-
lipidaemia and accumulation of FFA in the plasma after
TNF-a administration arise from an increased hepatic out-
put. The parallelism between plasma FFA and triglycerides
suggests that the increased triglyceride concentration in
plasma is due to esterification of FFA by the liver and
secretion as VLDL.
In conclusion our studies demonstrated that administrationMETABOLIC EFFECTS OF TNF 519
of TNF-a produces a complex series of metabolic changes,
which may represent a co-ordinated metabolic response to
infection or cachexia but which seem to be independent of
the effect on food and water intake. These conclusions apply
to the early effects of TNF-x and the action may be different
at later time points.
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